Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs.
dog
hepatocellular carcinoma
metronomic therapy
outcome
sorafenib
spontaneous model
toxicity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 May 2020
18 May 2020
Historique:
received:
03
04
2020
revised:
13
05
2020
accepted:
15
05
2020
entrez:
24
5
2020
pubmed:
24
5
2020
medline:
24
5
2020
Statut:
epublish
Résumé
Unresectable nodular and diffuse hepatocellular carcinoma (HCC) have a poor prognosis with limited treatment options. Systemic traditional chemotherapy has been only rarely reported, with unsatisfactory results. The aim of this prospective, non-randomized, non-blinded, single center clinical trial was to investigate safety profile, objective response rate, time to progression and overall survival of sorafenib in comparison with metronomic chemotherapy (MC) consisting of thalidomide, piroxicam and cyclophosphamide in dogs with advanced, unresectable HCC. Between December 2011 and June 2017, 13 dogs were enrolled: seven received sorafenib, and six were treated with MC. Median time to progression was 363 days (95% CI, 191-535) in dogs treated with sorafenib versus 27 days (95% CI, 0-68) in dogs treated with MC (
Identifiants
pubmed: 32443457
pii: cancers12051272
doi: 10.3390/cancers12051272
pmc: PMC7281367
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Cancers (Basel). 2020 Jan 18;12(1):
pubmed: 31963766
Sci Rep. 2017 Feb 13;7:42499
pubmed: 28211921
Vet Rec. 2016 Nov 19;179(20):514
pubmed: 27553604
Target Oncol. 2017 Dec;12(6):795-803
pubmed: 28770532
Oncologist. 2007 Apr;12(4):426-37
pubmed: 17470685
Eur J Pharmacol. 2011 Nov 16;670(1):39-43
pubmed: 21924262
J Vet Intern Med. 2007 Jul-Aug;21(4):764-9
pubmed: 17708397
Vet Comp Oncol. 2004 Dec;2(4):195-213
pubmed: 19379294
Vet Pathol. 1981 Jul;18(4):427-38
pubmed: 6266116
Vet Comp Oncol. 2011 Dec;9(4):260-8
pubmed: 22077406
Res Vet Sci. 2010 Feb;88(1):94-100
pubmed: 19665156
Vet Med (Auckl). 2017 Dec 08;8:97-102
pubmed: 30050861
Mol Cancer Res. 2017 Sep;15(9):1230-1242
pubmed: 28584024
Oncotarget. 2018 Jun 1;9(42):26868-26883
pubmed: 29928490
Cancer Lett. 2015 Mar 28;358(2):100-106
pubmed: 25541061
J Vet Intern Med. 2009 Jan-Feb;23(1):130-7
pubmed: 19175731
Vet Comp Oncol. 2018 Sep;16(3):399-408
pubmed: 29508493
Curr Med Chem. 2010;17(8):709-40
pubmed: 20088759
World J Gastroenterol. 2018 Sep 28;24(36):4152-4163
pubmed: 30271080
J Am Vet Med Assoc. 2004 Oct 15;225(8):1225-30
pubmed: 15521445
Oxid Med Cell Longev. 2018 Nov 4;2018:7512159
pubmed: 30524660
Vet Comp Oncol. 2015 Sep;13(3):176-83
pubmed: 23534501
Vet Comp Oncol. 2017 Jun;15(2):493-503
pubmed: 26792231
Mol Cancer Ther. 2013 Sep;12(9):1701-14
pubmed: 23804705
PLoS One. 2015 Apr 29;10(4):e0124889
pubmed: 25923466
Curr Pharm Des. 2002;8(25):2255-7
pubmed: 12369853
J Small Anim Pract. 2018 Feb;59(2):85-91
pubmed: 29210452
J Cancer Res Clin Oncol. 2018 Feb;144(2):403-414
pubmed: 29249005
Int J Mol Sci. 2019 Mar 26;20(6):
pubmed: 30917505
J Vet Intern Med. 2008 Nov-Dec;22(6):1373-9
pubmed: 18976288
Vet Radiol Ultrasound. 2016 Jan;57(1):75-83
pubmed: 26551348